Key result
Cardiac contractility modulation therapy improved left ventricular ejection fraction from 20-25% to 40-45% and NYHA functional class from III to I at 3 months in a patient with dilated cardiomyopathy.
Why the study?
Does cardiac contractility modulation therapy improve symptoms and cardiac function in a patient with dilated cardiomyopathy, narrow QRS, and reduced LVEF?
Population
1 35-year-old male with dilated cardiomyopathy, LVEF 25%, narrow QRS, NYHA class III despite…
Design
Case_report
Follow-up
3 months
Authors
Loading...
Hypothesis-generating for CCM in narrow-QRS HFrEF; prospective trials needed before adoption.
Case Report (n=1)
Does cardiac contractility modulation therapy improve symptoms and cardiac function in a patient with dilated cardiomyopathy, narrow QRS, and reduced LVEF?
Cardiac contractility modulation therapy may provide significant symptomatic and functional improvement in patients with HFrEF and narrow QRS who are refractory to medical therapy and ineligible for CRT.
Al‐Ghamdi et al. (2017) conducted a case report in Dilated cardiomyopathy with heart failure (n=1). Cardiac contractility modulation (CCM) vs. Baseline was evaluated on Left ventricular ejection fraction (LVEF). Cardiac contractility modulation therapy improved left ventricular ejection fraction from 20-25% to 40-45% and NYHA functional class from III to I at 3 months in a patient with dilated cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: